A BILL 
To amend the Comprehensive Addiction and Recovery Act 
of 2016 to authorize the Attorney General, in coordina-
tion with the Administrator of the Drug Enforcement 
Administration, the Secretary of Health and Human 
Services, and the Director of the Office of National Drug 
Control Policy, to award grants to covered entities to 
establish or maintain disposal sites for unwanted pre-
scription medications, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
02:07 Aug 25, 2021
H5086
2 
•HR 5086 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Safe Disposal of 
2
Opioids Act of 2021’’. 
3
SEC. 2. GRANTS FOR DISPOSAL SITES FOR UNWANTED PRE-
4
SCRIPTION MEDICATIONS. 
5
Section 203 of the Comprehensive Addiction and Re-
6
covery Act of 2016 (21 U.S.C. 822a) is amended by add-
7
ing at the end the following: 
8
‘‘(c) GRANTS FOR DISPOSAL SITES FOR UNWANTED 
9
PRESCRIPTION MEDICATIONS.— 
10
‘‘(1) GRANTS.— 
11
‘‘(A) AWARDS.—In carrying out subsection 
12
(b), the Attorney General shall award grants to 
13
covered entities to establish or maintain dis-
14
posal sites for unwanted prescription medica-
15
tions. 
16
‘‘(B) LIMITATION.—Of the total amount of 
17
awards under subparagraph (A) for a fiscal 
18
year, the Attorney General shall not award 
19
more than 10 percent to covered entities that 
20
are— 
21
‘‘(i) State, local, or tribal law enforce-
22
ment agencies; or 
23
‘‘(ii) manufacturers, distributors, or 
24
reverse distributors of prescription medica-
25
tions. 
26
02:07 Aug 25, 2021
H5086
3 
•HR 5086 IH
‘‘(2) DISCOUNTS FOR ELIGIBLE PATIENTS.— 
1
‘‘(A) IN
GENERAL.—The Secretary of 
2
Health and Human Services shall establish a 
3
mechanism by which amounts paid by an eligi-
4
ble patient for an active opioid are discounted 
5
at time of payment or purchase to ensure that 
6
such patient does not pay any amount attrib-
7
utable to a fee under paragraph (3), with as lit-
8
tle burden on the patient as possible. 
9
‘‘(B) DEFINITION.—For purposes of sub-
10
paragraph (A), the term ‘eligible patient’ 
11
means— 
12
‘‘(i) a patient for whom any active 
13
opioid (as so defined) is prescribed to treat 
14
pain relating to cancer or cancer treat-
15
ment; 
16
‘‘(ii) a patient participating in hospice 
17
care; and 
18
‘‘(iii) in the case of the death or inca-
19
pacity of a patient described in subpara-
20
graph (A) or (B) or any similar situation 
21
as determined by the Secretary of Health 
22
and Human Services, the appropriate fam-
23
ily member, medical proxy, or similar rep-
24
resentative or the estate of such patient. 
25
02:07 Aug 25, 2021
H5086
4 
•HR 5086 IH
‘‘(3) FEES.— 
1
‘‘(A) IN GENERAL.—There is hereby im-
2
posed on the sale of any active opioid by the 
3
manufacturer, producer, or importer a fee equal 
4
to 1 cent per 100 milligrams so sold. 
5
‘‘(B) SPECIAL RULES.— 
6
‘‘(i) DEFINITION.—In this paragraph, 
7
the term ‘active opioid’— 
8
‘‘(I) means any controlled sub-
9
stance (as defined in section 102 of 
10
the Controlled Substances Act, as in 
11
effect on the date of the Safe Disposal 
12
of Opioids Act of 2021) which is 
13
opium, an opiate, or any derivative 
14
thereof; and 
15
‘‘(II) excludes any prescribed 
16
drug which is used exclusively for the 
17
treatment of opioid addiction as part 
18
of a medically assisted treatment ef-
19
fort. 
20
‘‘(ii) EXCLUSION OF OTHER INGREDI-
21
ENTS.—In the case of a product that in-
22
cludes an active opioid and another ingre-
23
dient, subparagraph (A) shall apply only to 
24
02:07 Aug 25, 2021
H5086
5 
•HR 5086 IH
the portion of such product that is an ac-
1
tive opioid. 
2
‘‘(4) AUTHORIZATION
OF
APPROPRIATIONS.— 
3
For fiscal year 2022 and each subsequent fiscal 
4
year, there is authorized to be appropriated to carry 
5
out this subsection an amount not to exceed the ag-
6
gregate amount of the fees collected pursuant to 
7
paragraph (3).’’. 
8
Æ 
02:07 Aug 25, 2021
H5086
